Lucas Guimarães Campos Roriz de Amorim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lucas Guimarães Campos Roriz de Amorim has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Caio Hernandes Colhado
Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil
2 shared publications Eduardo Mazzucchi
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Brasil
2 shared publicationsEliabe Silva de Abreu
Mayo Clinic-Rochester, USA
2 shared publicationsGiovanni Scala Marchini
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Brasil
2 shared publicationsManoj Monga
UC San Diego Health, USA
2 shared publicationsMarcelo Esteves Chaves Campos
Universidade Federal de Minas Gerais, Brasil
2 shared publications
Latest Publications
- 24 August 2026
- Published by Springer Nature in International Urology and Nephrology
- p. 1-21
Minimally invasive treatments for benign prostatic obstruction: a systematic review and network meta-analysis of randomized controlled trials at 12 months
Purpose This network meta-analysis evaluates efficacy outcomes of established and emerging techniques to inform evidence-based clinical decision-making. Materials and methods PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials comparing minimally invasive treatments for benign prostatic hyperplasia. Primary outcomes encompassed urinary function, sexual function, safety, and durability. Network meta-analysis was conducted using MetaInsight. Results Among 36 randomized controlled trials and 4851 patients, no individual intervention significantly outperformed bTURP in either symptom control, peak urinary flow, hospital stay, complications, or medical retreatment at 12 months. PUL was the only technique significantly inferior to bTURP in bladder emptying (PVR: MD 67.47 mL; 95% CrI 11.02–125.79), yet demonstrated superior ejaculatory function preservation over mTURP/bTURP (MSHQ-EjD: MD 4.99; 95% CrI 1.32–8.64) without differences in ejaculatory bother. HoLEP showed significantly lower surgical retreatment rates versus bTURP and mTURP, and HoLEP and ThuLEP demonstrated shorter catheterization times versus bTURP (MD −36.26 h and −26.89 h, respectively). When grouped by category, stent/implant devices were significantly inferior to enucleation, ablation, and resection in urinary outcomes, yet demonstrated superior ejaculatory function preservation versus resection (MSHQ-EjD: MD 5.01; 95% CrI 1.33–8.65) without differences in ejaculatory bother. Enucleation was the only category with significantly reduced surgical retreatment versus sham. Conclusions No intervention surpassed bTURP in urinary efficacy. HoLEP demonstrated superior durability, while stent/implant approaches and PUL showed inferior urinary outcomes. Preservation of ejaculatory function with stent/implant techniques did not translate into reduced patient-reported bother.
- 24 August 2026
- Published by Springer Nature in International Urology and Nephrology
- p. 1-21
Minimally invasive treatments for benign prostatic obstruction: a systematic review and network meta-analysis of randomized controlled trials at 12 months
Purpose This network meta-analysis evaluates efficacy outcomes of established and emerging techniques to inform evidence-based clinical decision-making. Materials and methods PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials comparing minimally invasive treatments for benign prostatic hyperplasia. Primary outcomes encompassed urinary function, sexual function, safety, and durability. Network meta-analysis was conducted using MetaInsight. Results Among 36 randomized controlled trials and 4851 patients, no individual intervention significantly outperformed bTURP in either symptom control, peak urinary flow, hospital stay, complications, or medical retreatment at 12 months. PUL was the only technique significantly inferior to bTURP in bladder emptying (PVR: MD 67.47 mL; 95% CrI 11.02–125.79), yet demonstrated superior ejaculatory function preservation over mTURP/bTURP (MSHQ-EjD: MD 4.99; 95% CrI 1.32–8.64) without differences in ejaculatory bother. HoLEP showed significantly lower surgical retreatment rates versus bTURP and mTURP, and HoLEP and ThuLEP demonstrated shorter catheterization times versus bTURP (MD −36.26 h and −26.89 h, respectively). When grouped by category, stent/implant devices were significantly inferior to enucleation, ablation, and resection in urinary outcomes, yet demonstrated superior ejaculatory function preservation versus resection (MSHQ-EjD: MD 5.01; 95% CrI 1.33–8.65) without differences in ejaculatory bother. Enucleation was the only category with significantly reduced surgical retreatment versus sham. Conclusions No intervention surpassed bTURP in urinary efficacy. HoLEP demonstrated superior durability, while stent/implant approaches and PUL showed inferior urinary outcomes. Preservation of ejaculatory function with stent/implant techniques did not translate into reduced patient-reported bother.
- 6 February 2026
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 23 (3)
Efficacy of platelet-rich therapies versus placebo in the treatment of erectile dysfunction: an updated systematic review and meta-analysis of randomized controlled trials
Introduction: Platelet-rich therapies (PRTs), including platelet-rich plasma and platelet-rich fibrin matrix, have drawn attention as treatments for erectile dysfunction (ED). However, evidence regarding their effectiveness remains limited. Objectives: To determine the efficacy of PRTs in the treatment of ED. Methods: We performed a systematic search of PubMed, Embase, and Cochrane Library in April 2025 for studies comparing PRT with placebo in patients with ED. Pooled risk ratios, mean differences, and standardized mean differences with 95% CIs were calculated. We used the Grading of Recommendations Assessment, Development, and Evaluation tool to assess the certainty of evidence and strength of recommendations. The outcomes of interest were the mean change in the erectile function domain of the International Index of Erectile Function (IIEF) score, the rate of men achieving minimum clinically important difference (MCID) in the IIEF-EF score, peak systolic velocity (PSV), end diastolic velocity (EDV), and visual analogue scale (VAS) pain score after injection. Results: We included seven randomized controlled trials (RCTs) comprising 479 patients, of whom 239 (49.9%) were randomized to PRTs. There were no differences between PRTs and placebo in the combined IIEF score at 1, 3, and 6 months of follow-up. There was no difference between groups in terms of the rate of men achieving MCID in IIEF-EF at 1 month, and at 3 months. PRTs showed a significantly higher rate of men achieving MCID in IIEF-EF at 6 months; however, it is noteworthy that only 3 studies provided data for this outcome, which may limit the robustness and generalizability of this result, thus should be interpreted with caution. There were no differences between groups in the PSV, EDV, and VAS pain score after injection. Conclusion: This meta-analysis of RCTs provides low-to-moderate certainty evidence that PRTs do not confer superior efficacy over placebo in improving sexual function in men with ED. However, the small number of patients restricts the generalizability of our conclusions. Additional high-quality studies are required to clarify the clinical role of PRTs in the management of ED.
- 6 February 2026
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 23 (3)
Efficacy of platelet-rich therapies versus placebo in the treatment of erectile dysfunction: an updated systematic review and meta-analysis of randomized controlled trials
Introduction: Platelet-rich therapies (PRTs), including platelet-rich plasma and platelet-rich fibrin matrix, have drawn attention as treatments for erectile dysfunction (ED). However, evidence regarding their effectiveness remains limited. Objectives: To determine the efficacy of PRTs in the treatment of ED. Methods: We performed a systematic search of PubMed, Embase, and Cochrane Library in April 2025 for studies comparing PRT with placebo in patients with ED. Pooled risk ratios, mean differences, and standardized mean differences with 95% CIs were calculated. We used the Grading of Recommendations Assessment, Development, and Evaluation tool to assess the certainty of evidence and strength of recommendations. The outcomes of interest were the mean change in the erectile function domain of the International Index of Erectile Function (IIEF) score, the rate of men achieving minimum clinically important difference (MCID) in the IIEF-EF score, peak systolic velocity (PSV), end diastolic velocity (EDV), and visual analogue scale (VAS) pain score after injection. Results: We included seven randomized controlled trials (RCTs) comprising 479 patients, of whom 239 (49.9%) were randomized to PRTs. There were no differences between PRTs and placebo in the combined IIEF score at 1, 3, and 6 months of follow-up. There was no difference between groups in terms of the rate of men achieving MCID in IIEF-EF at 1 month, and at 3 months. PRTs showed a significantly higher rate of men achieving MCID in IIEF-EF at 6 months; however, it is noteworthy that only 3 studies provided data for this outcome, which may limit the robustness and generalizability of this result, thus should be interpreted with caution. There were no differences between groups in the PSV, EDV, and VAS pain score after injection. Conclusion: This meta-analysis of RCTs provides low-to-moderate certainty evidence that PRTs do not confer superior efficacy over placebo in improving sexual function in men with ED. However, the small number of patients restricts the generalizability of our conclusions. Additional high-quality studies are required to clarify the clinical role of PRTs in the management of ED.
- Open Access
- 5 December 2025
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 51 (5) , 179-188
Tadalafil Versus Tamsulosin or Silodosin as Medical Expulsive Therapy for Distal Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: Medical expulsive therapy (MET) facilitates the passage of distal ureteric stones. Alpha-blockers are the standard MET strategy. However, there has been grow ing interest in using tadalafil, a Phosphodiesterase type 5 (PDE5) inhibitor, to facilitate ureteral stone passage. Therefore, a systematic review and meta-analysis comparing tadalafil versus tamsulosin or silodosin was conducted as MET options for patients with distal ureteral stones. Methods: PubMed, Embase, and Cochrane Library were systematically searched in September 2023 for randomized controlled trials (RCTs) comparing tadalafil with alpha-blockers (tamsulosin or silodosin) for distal ureteric stones. Outcomes included stone expulsion rate (SER), stone expulsion time (SET), colic episodes, analgesic use, and side effects. Review Manager 5.4.1 was used for statistical analysis, applying a ran dom-effects model. Results: Eleven RCTs were included with 1345 patients, 579 (43%) randomized to tadalafil. No significant differences were found between groups for SER (risk ratio [RR] 1.07; 95% CI 0.98-1.18; P = .14), SET (RR −0.68; 95% CI −1.75 to 0.38; P = .21), colic epi sodes, or analgesic use. Headaches were significantly less frequent with alpha-blockers (RR 1.50; 95% CI 1.09-2.04; P = .01), while abnormal ejaculation was significantly less frequent in the tadalafil group (RR 0.38; 95% CI 0.19-0.74; P = .005). Conclusion: Given the comparable efficacy in stone expulsion and the distinct side effect profiles, the choice between tadalafil and alpha-blockers for MET can be individ ualized. Tadalafil emerges as a strong MET alternative, particularly when alpha-blockers are contraindicated or poorly tolerated. Cite this article as: Sanches MR, Amorim LGCRd, Moreira MVB, et al. Tadalafil versus tamsulosin or silodosin as medical expulsive therapy for distal ureteral stones: A systematic review and meta-analysis of randomized controlled trials. Urol Res Pract. 2025;51(5):179-188.
- 5 December 2025
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 51 (5) , 179-188
Open AccessTadalafil Versus Tamsulosin or Silodosin as Medical Expulsive Therapy for Distal Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: Medical expulsive therapy (MET) facilitates the passage of distal ureteric stones. Alpha-blockers are the standard MET strategy. However, there has been grow ing interest in using tadalafil, a Phosphodiesterase type 5 (PDE5) inhibitor, to facilitate ureteral stone passage. Therefore, a systematic review and meta-analysis comparing tadalafil versus tamsulosin or silodosin was conducted as MET options for patients with distal ureteral stones. Methods: PubMed, Embase, and Cochrane Library were systematically searched in September 2023 for randomized controlled trials (RCTs) comparing tadalafil with alpha-blockers (tamsulosin or silodosin) for distal ureteric stones. Outcomes included stone expulsion rate (SER), stone expulsion time (SET), colic episodes, analgesic use, and side effects. Review Manager 5.4.1 was used for statistical analysis, applying a ran dom-effects model. Results: Eleven RCTs were included with 1345 patients, 579 (43%) randomized to tadalafil. No significant differences were found between groups for SER (risk ratio [RR] 1.07; 95% CI 0.98-1.18; P = .14), SET (RR −0.68; 95% CI −1.75 to 0.38; P = .21), colic epi sodes, or analgesic use. Headaches were significantly less frequent with alpha-blockers (RR 1.50; 95% CI 1.09-2.04; P = .01), while abnormal ejaculation was significantly less frequent in the tadalafil group (RR 0.38; 95% CI 0.19-0.74; P = .005). Conclusion: Given the comparable efficacy in stone expulsion and the distinct side effect profiles, the choice between tadalafil and alpha-blockers for MET can be individ ualized. Tadalafil emerges as a strong MET alternative, particularly when alpha-blockers are contraindicated or poorly tolerated. Cite this article as: Sanches MR, Amorim LGCRd, Moreira MVB, et al. Tadalafil versus tamsulosin or silodosin as medical expulsive therapy for distal ureteral stones: A systematic review and meta-analysis of randomized controlled trials. Urol Res Pract. 2025;51(5):179-188.
- 29 September 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 585
Single-session bilateral vs. staged unilateral renal stone removal: comparative outcomes in a systematic review and meta-analysis
There is still controversy regarding the best approach to bilateral renal urolithiasis. Single-session bilateral (SSB) renal stone removal is considered superior due to fewer procedures and less anesthesia exposure. However, doubts persist about its effectiveness and safety compared to staged unilateral (SU) procedures, particularly concerning complications and stone-free rates (SFR). We conducted a systematic review and meta-analysis to compare outcomes of these approaches. We hypothesize that SSB procedures have similar outcomes in terms of complications and SFR with fewer interventions. A meta-analysis following Cochrane and PRISMA guidelines included studies from 2002 to 2024 comparing SSB to SU procedures. Searches were conducted in PubMed, Cochrane, and EMBASE, focusing on complication rates, SFR, operative time, and additional procedures. The search yielded 13 studies with a total of 836,414 patients, of which 7,854 were in the SSB group. The rate of severe complications (Clavien-Dindo grade ≥ 3) was not significantly different between SSB versus SU groups (RR 1.22; 95% CI 0.65-2.26; P = 0.53). Nevertheless, overall complication rates were notably higher for SSB procedures (RR 1.32; 95% CI 1.08-1.62; P = 0.007). SFR was similar between approaches (RR 0.89; 95% CI 0.74-1.07; P = 0.23). Importantly, SSB procedures resulted in significantly longer operative times (MD 27.93 minutes; 95% CI 7.78-48.07; P = 0.007) and had a significantly higher need for unplanned additional interventions (RR 1.65; 95% CI 1.44-1.89; P < 0.00001).The search yielded 13 studies with a total of 836,414 patients, of which 7,854 were in the SSB group. The rate of severe complications (Clavien-Dindo grade ≥ 3) was not significantly different between SSB versus SU groups (RR 1.22; 95% CI 0.65-2.26; P = 0.53). Nevertheless, overall complication rates were notably higher for SSB procedures (RR 1.32; 95% CI 1.08-1.62; P = 0.007). SFR was similar between approaches (RR 0.89; 95% CI 0.74-1.07; P = 0.23). Importantly, SSB procedures resulted in significantly longer operative times (MD 27.93 minutes; 95% CI 7.78-48.07; P = 0.007) and had a significantly higher need for unplanned additional interventions (RR 1.65; 95% CI 1.44-1.89; P < 0.00001). SSB procedures achieve similar SFR and severe complication rates as SU procedures but involve longer operative times and higher overall complication rates. Their advantage lies in reducing planned surgical sessions, offering fewer anesthesia exposures, though this benefit is offset by an increased need for unplanned additional procedures.
- 29 September 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 585
Single-session bilateral vs. staged unilateral renal stone removal: comparative outcomes in a systematic review and meta-analysis
There is still controversy regarding the best approach to bilateral renal urolithiasis. Single-session bilateral (SSB) renal stone removal is considered superior due to fewer procedures and less anesthesia exposure. However, doubts persist about its effectiveness and safety compared to staged unilateral (SU) procedures, particularly concerning complications and stone-free rates (SFR). We conducted a systematic review and meta-analysis to compare outcomes of these approaches. We hypothesize that SSB procedures have similar outcomes in terms of complications and SFR with fewer interventions. A meta-analysis following Cochrane and PRISMA guidelines included studies from 2002 to 2024 comparing SSB to SU procedures. Searches were conducted in PubMed, Cochrane, and EMBASE, focusing on complication rates, SFR, operative time, and additional procedures. The search yielded 13 studies with a total of 836,414 patients, of which 7,854 were in the SSB group. The rate of severe complications (Clavien-Dindo grade ≥ 3) was not significantly different between SSB versus SU groups (RR 1.22; 95% CI 0.65-2.26; P = 0.53). Nevertheless, overall complication rates were notably higher for SSB procedures (RR 1.32; 95% CI 1.08-1.62; P = 0.007). SFR was similar between approaches (RR 0.89; 95% CI 0.74-1.07; P = 0.23). Importantly, SSB procedures resulted in significantly longer operative times (MD 27.93 minutes; 95% CI 7.78-48.07; P = 0.007) and had a significantly higher need for unplanned additional interventions (RR 1.65; 95% CI 1.44-1.89; P < 0.00001).The search yielded 13 studies with a total of 836,414 patients, of which 7,854 were in the SSB group. The rate of severe complications (Clavien-Dindo grade ≥ 3) was not significantly different between SSB versus SU groups (RR 1.22; 95% CI 0.65-2.26; P = 0.53). Nevertheless, overall complication rates were notably higher for SSB procedures (RR 1.32; 95% CI 1.08-1.62; P = 0.007). SFR was similar between approaches (RR 0.89; 95% CI 0.74-1.07; P = 0.23). Importantly, SSB procedures resulted in significantly longer operative times (MD 27.93 minutes; 95% CI 7.78-48.07; P = 0.007) and had a significantly higher need for unplanned additional interventions (RR 1.65; 95% CI 1.44-1.89; P < 0.00001). SSB procedures achieve similar SFR and severe complication rates as SU procedures but involve longer operative times and higher overall complication rates. Their advantage lies in reducing planned surgical sessions, offering fewer anesthesia exposures, though this benefit is offset by an increased need for unplanned additional procedures.
- 22 February 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (8) , 3465-3476
Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis
Purpose Treatment for metastatic castration-resistant prostate cancer (mCRPC) includes chemotherapy and inhibition of the androgen receptor pathway. However, the optimal treatment sequence in this scenario is not yet fully understood. Therefore, we conducted a systematic review and meta-analysis comparing cabazitaxel versus abiraterone or enzalutamide for efficacy and safety outcomes as second-line therapy in mCRPC patients after docetaxel failure. Methods We searched PubMed, Embase, and Cochrane databases for interventional studies comparing cabazitaxel versus abiraterone or enzalutamide for patients with mCRPC who have experienced treatment failure with docetaxel as their first-line therapy. We computed hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs). Results Eight studies, comprising 1,897 patients were included, of whom 548 (28.8%) received cabazitaxel. Mean follow-up time ranged from 3 to 16.4 months. Median age ranged from 68.1 to 73.9 years in the cabazitaxel group, and 68.0 to 73.1 years in the abiraterone or enzalutamide group. In our meta-analysis, cabazitaxel significantly improved progression-free survival (PFS) rates (HR 0.60; 95% CI 0.47–0.78; p < 0.001) compared to abiraterone or enzalutamide. There were no differences between groups in overall survival (HR 0.76; 95% CI 0.46–1.24; p = 0.27), therapy-related grade ≥ 3 adverse events (AEs) (OR 3.00; 95% CI 0.72–12.40; p = 0.12), and PSA decline ≥ 50% (OR 1.20; 95% CI 0.51–2.80; p = 0.67). Conclusions In this systematic review and meta-analysis of men with mCRPC after docetaxel failure, second-line therapy with cabazitaxel was associated with a longer PFS compared with abiraterone or enzalutamide, though without a significant difference in OS.
- 22 February 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (8) , 3465-3476
Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis
Purpose Treatment for metastatic castration-resistant prostate cancer (mCRPC) includes chemotherapy and inhibition of the androgen receptor pathway. However, the optimal treatment sequence in this scenario is not yet fully understood. Therefore, we conducted a systematic review and meta-analysis comparing cabazitaxel versus abiraterone or enzalutamide for efficacy and safety outcomes as second-line therapy in mCRPC patients after docetaxel failure. Methods We searched PubMed, Embase, and Cochrane databases for interventional studies comparing cabazitaxel versus abiraterone or enzalutamide for patients with mCRPC who have experienced treatment failure with docetaxel as their first-line therapy. We computed hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs). Results Eight studies, comprising 1,897 patients were included, of whom 548 (28.8%) received cabazitaxel. Mean follow-up time ranged from 3 to 16.4 months. Median age ranged from 68.1 to 73.9 years in the cabazitaxel group, and 68.0 to 73.1 years in the abiraterone or enzalutamide group. In our meta-analysis, cabazitaxel significantly improved progression-free survival (PFS) rates (HR 0.60; 95% CI 0.47–0.78; p < 0.001) compared to abiraterone or enzalutamide. There were no differences between groups in overall survival (HR 0.76; 95% CI 0.46–1.24; p = 0.27), therapy-related grade ≥ 3 adverse events (AEs) (OR 3.00; 95% CI 0.72–12.40; p = 0.12), and PSA decline ≥ 50% (OR 1.20; 95% CI 0.51–2.80; p = 0.67). Conclusions In this systematic review and meta-analysis of men with mCRPC after docetaxel failure, second-line therapy with cabazitaxel was associated with a longer PFS compared with abiraterone or enzalutamide, though without a significant difference in OS.
- Open Access
- 1 December 2024
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 50 (6) , 670-682
Retrograde intrarenal surgery with or without ureteral access sheath: a systematic review and meta-analysis of randomized controlled trials
The ureteral access sheath (UAS) is a medical device that enables repeated entrance into the ureter and collecting system during retrograde intrarenal surgery (RIRS). Its impact on stone-free rates, ureteral injuries, operative time, and postoperative complications remains controversial. Therefore, we performed a systematic review and meta-analysis comparing RIRS with versus without UAS for urolithiasis management.
- 1 December 2024
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 50 (6) , 670-682
Open AccessRetrograde intrarenal surgery with or without ureteral access sheath: a systematic review and meta-analysis of randomized controlled trials
The ureteral access sheath (UAS) is a medical device that enables repeated entrance into the ureter and collecting system during retrograde intrarenal surgery (RIRS). Its impact on stone-free rates, ureteral injuries, operative time, and postoperative complications remains controversial. Therefore, we performed a systematic review and meta-analysis comparing RIRS with versus without UAS for urolithiasis management.
- Open Access
- 1 November 2024
- Vol. 50 (6) , 670-682
Retrograde intrarenal surgery with or without ureteral access sheath: a systematic review and meta-analysis of randomized controlled trials
Introduction: The ureteral access sheath (UAS) is a medical device that enables repeated entrance into the ureter and collecting system during retrograde intrarenal surgery (RIRS). Its impact on stone-free rates, ureteral injuries, operative time, and postoperative complica-tions remains controversial. Therefore, we performed a systematic review and meta-analy-sis comparing RIRS with versus without UAS for urolithiasis management.Purpose: To compare outcomes from retrograde intrarenal surgery (RIRS) for stone extrac-tion with or without ureteral access sheath (UAS); evaluating stone-free rate (SFR), ureteral injuries, operative time, and postoperative complications.Materials and Methods: We systematically searched PubMed, Embase, and Cochrane Li-brary in June 2024 for randomized controlled trials (RCTs) evaluating the eff icacy and safety outcomes of UAS use in RIRS for urolithiasis treatment. Articles published between 2014 and 2024 were included. Pooled risk ratios (RRs) and mean diff erences (MDs) were calculated for binary and continuous outcomes, respectively.Results: Five RCTs comprising 466 procedures were included. Of these, 246 (52.7%) utilized UAS. The follow-up ranged from 1 week to 1 month. UAS reduced the incidence of postopera-tive fever (RR 0.49; 95% confidence interval [CI] 0.29-0.84; p=0.009), and postoperative in-fection (RR 0.50; 95% CI 0.30-0.83; p=0.008). There were no significant diff erences between groups in terms of SFR (RR 1.05; 95% CI 0.99-1.11; p=0.10), ureteral injuries (RR 1.29; 95% CI 0.95-1.75; p=0.11), operative time (MD 3.56 minutes; 95% CI -4.15 to 11.27 minutes; p=0.36), or length of stay (MD 0.32 days; 95% CI -0.42 to 1.07 days; p=0.40).Conclusion: UAS leads to a lower rate of post-operative fever and infection. However, UAS did not significantly reduce or increase the SFR or the rate of ureteral injuries during RIRS for patients with urolithiasis. The use of UAS should be considered to decrease the risk of infec-tious complications, particularly in those who may be at higher risk for such complications.
- 1 November 2024
- Vol. 50 (6) , 670-682
Open AccessRetrograde intrarenal surgery with or without ureteral access sheath: a systematic review and meta-analysis of randomized controlled trials
Introduction: The ureteral access sheath (UAS) is a medical device that enables repeated entrance into the ureter and collecting system during retrograde intrarenal surgery (RIRS). Its impact on stone-free rates, ureteral injuries, operative time, and postoperative complica-tions remains controversial. Therefore, we performed a systematic review and meta-analy-sis comparing RIRS with versus without UAS for urolithiasis management.Purpose: To compare outcomes from retrograde intrarenal surgery (RIRS) for stone extrac-tion with or without ureteral access sheath (UAS); evaluating stone-free rate (SFR), ureteral injuries, operative time, and postoperative complications.Materials and Methods: We systematically searched PubMed, Embase, and Cochrane Li-brary in June 2024 for randomized controlled trials (RCTs) evaluating the eff icacy and safety outcomes of UAS use in RIRS for urolithiasis treatment. Articles published between 2014 and 2024 were included. Pooled risk ratios (RRs) and mean diff erences (MDs) were calculated for binary and continuous outcomes, respectively.Results: Five RCTs comprising 466 procedures were included. Of these, 246 (52.7%) utilized UAS. The follow-up ranged from 1 week to 1 month. UAS reduced the incidence of postopera-tive fever (RR 0.49; 95% confidence interval [CI] 0.29-0.84; p=0.009), and postoperative in-fection (RR 0.50; 95% CI 0.30-0.83; p=0.008). There were no significant diff erences between groups in terms of SFR (RR 1.05; 95% CI 0.99-1.11; p=0.10), ureteral injuries (RR 1.29; 95% CI 0.95-1.75; p=0.11), operative time (MD 3.56 minutes; 95% CI -4.15 to 11.27 minutes; p=0.36), or length of stay (MD 0.32 days; 95% CI -0.42 to 1.07 days; p=0.40).Conclusion: UAS leads to a lower rate of post-operative fever and infection. However, UAS did not significantly reduce or increase the SFR or the rate of ureteral injuries during RIRS for patients with urolithiasis. The use of UAS should be considered to decrease the risk of infec-tious complications, particularly in those who may be at higher risk for such complications.